Literature DB >> 23636733

Alternative drugs of abuse.

M E Sutter1, J Chenoweth, T E Albertson.   

Abstract

The incidence of drug abuse with alternative agents is increasing. The term "alternative drugs of abuse" is a catch-all term for abused chemicals that do not fit into one of the classic categories of drugs of abuse. The most common age group abusing these agents range from 17 to 25 years old and are often associated with group settings. Due to their diverse pharmacological nature, legislative efforts to classify these chemicals as a schedule I drug have lagged behind the development of new alternative agents. The potential reason for abuse of these agents is their hallucinogenic, dissociative, stimulant, anti-muscarinic, or sedative properties. Some of these drugs are easily obtainable such as Datura stramonium (Jimson Weed) or Lophophora williamsii (Peyote) because they are natural plants indigenous to certain regions. The diverse pharmacology and clinical effects of these agents are so broad that they do not produce a universal constellation of signs and symptoms. Detailed physical exams are essential for identifying clues leading one to suspect an alternative drug of abuse. Testing for the presence of these agents is often limited, and even when available, the results do not return in a timely fashion. Intoxications from these agents pose unique challenges for health care providers. Physician knowledge of the physiological effects of these alternative agents and the local patterns of drug of abuse are important for the accurate diagnosis and optimal care of poisoned patients. This review summarizes the current knowledge of alternative drugs of abuse and highlights their clinical presentations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23636733     DOI: 10.1007/s12016-013-8370-2

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  141 in total

Review 1.  Ketamine-snorting associated cystitis.

Authors:  Chung-Hsien Chen; Ming-Huei Lee; Yi-Chang Chen; Ming-Fong Lin
Journal:  J Formos Med Assoc       Date:  2011-12-27       Impact factor: 3.282

Review 2.  Gamma hydroxybutyrate (GHB): report of a mass intoxication and review of the literature.

Authors:  M Eckstein; S O Henderson; P DelaCruz; E Newton
Journal:  Prehosp Emerg Care       Date:  1999 Oct-Dec       Impact factor: 3.077

3.  Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels.

Authors:  R J Hoffman; R S Hoffman; C L Freyberg; R H Poppenga; L S Nelson
Journal:  J Toxicol Clin Toxicol       Date:  2001

4.  Amanita phalloides poisoning.

Authors:  Loren Keith French; Robert G Hendrickson; B Zane Horowitz
Journal:  Clin Toxicol (Phila)       Date:  2011-02       Impact factor: 4.467

5.  Long lasting effects of LSD on normals.

Authors:  W McGlothlin; S Cohen; M S McGlothlin
Journal:  Arch Gen Psychiatry       Date:  1967-11

6.  Jimsonweed (Datura stramonium) exposures in Texas, 1998-2004.

Authors:  Mathias B Forrester
Journal:  J Toxicol Environ Health A       Date:  2006-10

Review 7.  Ecstasy and other club drugs: a review of recent epidemiologic studies.

Authors:  Kit Sang Leung; Linda B Cottler
Journal:  Curr Opin Psychiatry       Date:  2008-05       Impact factor: 4.741

Review 8.  From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid.

Authors:  C Guin Ting Wong; K Michael Gibson; O Carter Snead
Journal:  Trends Pharmacol Sci       Date:  2004-01       Impact factor: 14.819

9.  Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia.

Authors:  David G E Caldicott; Fiona Y Chow; Brian J Burns; Peter D Felgate; Roger W Byard
Journal:  Med J Aust       Date:  2004-09-20       Impact factor: 7.738

10.  Acute phencyclidine intoxication: clinical patterns, complications, and treatment.

Authors:  M M McCarron; B W Schulze; G A Thompson; M C Conder; W A Goetz
Journal:  Ann Emerg Med       Date:  1981-06       Impact factor: 5.721

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.